Skip to main content
NCBI home page
Gut logoLink to Gut
. 2001 May;48(5):714–718. doi: 10.1136/gut.48.5.714

Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease

H Tillmann 1, D Chen 1, C Trautwein 1, V Kliem 1, A Grundey 1, A Berning-Haag 1, K Boker 1, S Kubicka 1, L Pastucha 1, W Stangel 1, M Manns 1
PMCID: PMC1728277  PMID: 11302974

Abstract

Hepatitis C virus (HCV) infection becomes chronic in more than 70% of patients, leading to end stage liver disease in about 20-30% of these patients. Apart from the virus itself, host factors that modulate the immune response are likely to be involved in determining the outcome of HCV infection. Studies on the association of human leucocyte antigens (HLAs) and HCV infection have shown inconsistent results. Selection of patient subgroups may be crucial. However, any association relevant to HCV disease progression will become evident, especially in those patients with end stage liver disease. Therefore, we analysed the phenotype frequencies of HLA antigens in two groups of 69 and 39 patients with HCV induced liver cirrhosis who had received a transplant or were awaiting liver transplantation. The first group was typed serologically and compared with 331 blood and liver donors. The second group, prospectively HLA typed by a polymerase chain reaction-sequence specific oligonucleotide (PCR-SSO) procedure for HLA-DRB and DQB alleles, was compared with another 170 PCR-SSO typed and randomly selected blood donors. Decreased frequencies for HLA-DR5 and HLA-DQ3 were found in one group of patients with HCV induced liver cirrhosis compared with the control groups. In the second analysis comparing 39 patients with end stage liver cirrhosis with blood donors, we confirmed the significant decrease in HLA-DRB1*11 and HLA-DQB1*03, which corresponded to serological HLA-DR5 and HLA-DQ3 antigens, respectively. Our results show that the presence of HLA-DRB1*11 and HLA-DQB1*03 alleles is associated with a reduced risk for the development of HCV induced end stage liver disease.


Keywords: hepatitis C; HLA; liver cirrhosis; immunogenetics; hepatocellular carcinoma; genotype

Full Text

The Full Text of this article is available as a PDF (119.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aikawa T., Kojima M., Onishi H., Tamura R., Fukuda S., Suzuki T., Tsuda F., Okamoto H., Miyakawa Y., Mayumi M. HLA DRB1 and DQB1 alleles and haplotypes influencing the progression of hepatitis C. J Med Virol. 1996 Aug;49(4):274–278. doi: 10.1002/(SICI)1096-9071(199608)49:4<274::AID-JMV3>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  2. Alric L., Fort M., Izopet J., Vinel J. P., Charlet J. P., Selves J., Puel J., Pascal J. P., Duffaut M., Abbal M. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology. 1997 Nov;113(5):1675–1681. doi: 10.1053/gast.1997.v113.pm9352872. [DOI] [PubMed] [Google Scholar]
  3. Alter M. J. Epidemiology of hepatitis C in the West. Semin Liver Dis. 1995 Feb;15(1):5–14. doi: 10.1055/s-2007-1007259. [DOI] [PubMed] [Google Scholar]
  4. Asti M., Martinetti M., Zavaglia C., Cuccia M. C., Gusberti L., Tinelli C., Cividini A., Bruno S., Salvaneschi L., Ideo G. Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease. Hepatology. 1999 Apr;29(4):1272–1279. doi: 10.1002/hep.510290445. [DOI] [PubMed] [Google Scholar]
  5. Ballardini G., Groff P., Pontisso P., Giostra F., Francesconi R., Lenzi M., Zauli D., Alberti A., Bianchi F. B. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C. J Clin Invest. 1995 May;95(5):2067–2075. doi: 10.1172/JCI117893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Barrett S., Ryan E., Crowe J. Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J Hepatol. 1999 Jun;30(6):979–983. doi: 10.1016/s0168-8278(99)80249-9. [DOI] [PubMed] [Google Scholar]
  7. Bjøro K., Frøland S. S., Yun Z., Samdal H. H., Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med. 1994 Dec 15;331(24):1607–1611. doi: 10.1056/NEJM199412153312402. [DOI] [PubMed] [Google Scholar]
  8. Botarelli P., Brunetto M. R., Minutello M. A., Calvo P., Unutmaz D., Weiner A. J., Choo Q. L., Shuster J. R., Kuo G., Bonino F. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology. 1993 Feb;104(2):580–587. doi: 10.1016/0016-5085(93)90430-k. [DOI] [PubMed] [Google Scholar]
  9. Chen D. F., Endres W., Kliem V., Tillmann H. L., Brunkhorst R., Koch K. M., Manns M. P., Stangel W. No significant influence of HLA determinants on susceptibility to hepatitis C virus infection in Caucasian patients with end-stage renal disease. Liver. 1996 Dec;16(6):384–389. doi: 10.1111/j.1600-0676.1996.tb00767.x. [DOI] [PubMed] [Google Scholar]
  10. Chen D. F., Endres W., Meyer S. A., Stangel W. A polymerase chain reaction-sequence-specific oligonucleotide procedure for HLA class II typing using biotin- and digoxigenin-labeled probes simultaneously in hybridization. Hum Immunol. 1994 Jan;39(1):25–30. doi: 10.1016/0198-8859(94)90097-3. [DOI] [PubMed] [Google Scholar]
  11. Chen D. F., Endres W., Meyer S. A., Stangel W. Simplified PCR-SSO procedure for DQA and DQB typing. Simultaneous hybridization of two probes to one membrane. Hum Immunol. 1996 Apr;46(2):120–123. doi: 10.1016/0198-8859(96)00013-4. [DOI] [PubMed] [Google Scholar]
  12. Christie J. M., Healey C. J., Watson J., Wong V. S., Duddridge M., Snowden N., Rosenberg W. M., Fleming K. A., Chapel H., Chapman R. W. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol. 1997 Oct;110(1):4–8. doi: 10.1046/j.1365-2249.1997.5081412.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cramp M. E., Carucci P., Underhill J., Naoumov N. V., Williams R., Donaldson P. T. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol. 1998 Aug;29(2):207–213. doi: 10.1016/s0168-8278(98)80005-6. [DOI] [PubMed] [Google Scholar]
  14. Czaja A. J., Carpenter H., Santrach P. J., Moore S. B. DR human leukocyte antigens and disease severity in chronic hepatitis C. J Hepatol. 1996 Jun;24(6):666–673. doi: 10.1016/s0168-8278(96)80261-3. [DOI] [PubMed] [Google Scholar]
  15. Diepolder H. M., Zachoval R., Hoffmann R. M., Wierenga E. A., Santantonio T., Jung M. C., Eichenlaub D., Pape G. R. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 1995 Oct 14;346(8981):1006–1007. doi: 10.1016/s0140-6736(95)91691-1. [DOI] [PubMed] [Google Scholar]
  16. Fanning L. J., Levis J., Kenny-Walsh E., Wynne F., Whelton M., Shanahan F. Viral clearance in hepatitis C (1b) infection: relationship with human leukocyte antigen class II in a homogeneous population. Hepatology. 2000 Jun;31(6):1334–1337. doi: 10.1053/jhep.2000.7437. [DOI] [PubMed] [Google Scholar]
  17. Gruber A., Lundberg L. G., Björkholm M. Reactivation of chronic hepatitis C after withdrawal of immunosuppressive therapy. J Intern Med. 1993 Aug;234(2):223–225. doi: 10.1111/j.1365-2796.1993.tb00734.x. [DOI] [PubMed] [Google Scholar]
  18. Higashi Y., Kamikawaji N., Suko H., Ando M. Analysis of HLA alleles in Japanese patients with cirrhosis due to chronic hepatitis C. J Gastroenterol Hepatol. 1996 Mar;11(3):241–246. doi: 10.1111/j.1440-1746.1996.tb00069.x. [DOI] [PubMed] [Google Scholar]
  19. Höhler T., Gerken G., Notghi A., Knolle P., Lubjuhn R., Taheri H., Schneider P. M., Meyer zum Büschenfelde K. H., Rittner C. MHC class II genes influence the susceptibility to chronic active hepatitis C. J Hepatol. 1997 Aug;27(2):259–264. doi: 10.1016/s0168-8278(97)80169-9. [DOI] [PubMed] [Google Scholar]
  20. Höhler T., Gerken G., Schneider P. M., Meyer zum Büschenfelde K. H., Rittner C. Antigen-processing polymorphisms in chronic hepatitis C infection. Exp Clin Immunogenet. 1996;13(1):7–11. [PubMed] [Google Scholar]
  21. Ishii K., Rosa D., Watanabe Y., Katayama T., Harada H., Wyatt C., Kiyosawa K., Aizaki H., Matsuura Y., Houghton M. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology. 1998 Oct;28(4):1117–1120. doi: 10.1002/hep.510280429. [DOI] [PubMed] [Google Scholar]
  22. Karayiannis P., Alexopoulou A., Hadziyannis S., Thursz M., Watts R., Seito S., Thomas H. C. Fulminant hepatitis associated with hepatitis B virus e antigen-negative infection: importance of host factors. Hepatology. 1995 Dec;22(6):1628–1634. [PubMed] [Google Scholar]
  23. Kuzushita N., Hayashi N., Katayama K., Hiramatsu N., Yasumaru M., Murata H., Shimizu Y., Yamazaki T., Fushimi H., Kotoh K. Increased frequency of HLA DR13 in hepatitis C virus carriers with persistently normal ALT levels. J Med Virol. 1996 Jan;48(1):1–7. doi: 10.1002/(SICI)1096-9071(199601)48:1<1::AID-JMV1>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  24. Lau J. Y., Davis G. L., Kniffen J., Qian K. P., Urdea M. S., Chan C. S., Mizokami M., Neuwald P. D., Wilber J. C. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 1993 Jun 12;341(8859):1501–1504. doi: 10.1016/0140-6736(93)90635-t. [DOI] [PubMed] [Google Scholar]
  25. Lechmann M., Schneider E. M., Giers G., Kaiser R., Dumoulin F. L., Sauerbruch T., Spengler U. Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. Eur J Clin Invest. 1999 Apr;29(4):337–343. doi: 10.1046/j.1365-2362.1999.00464.x. [DOI] [PubMed] [Google Scholar]
  26. Malkovsky M. HLA and natural history of HIV infection. Lancet. 1996 Jul 20;348(9021):142–143. doi: 10.1016/s0140-6736(05)66106-5. [DOI] [PubMed] [Google Scholar]
  27. Mangia A., Gentile R., Cascavilla I., Margaglione M., Villani M. R., Stella F., Modola G., Agostiano V., Gaudiano C., Andriulli A. HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol. 1999 Jun;30(6):984–989. doi: 10.1016/s0168-8278(99)80250-5. [DOI] [PubMed] [Google Scholar]
  28. Michitaka K., Durazzo M., Tillmann H. L., Walker D., Philipp T., Manns M. P. Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology. 1994 Jun;106(6):1603–1610. doi: 10.1016/0016-5085(94)90417-0. [DOI] [PubMed] [Google Scholar]
  29. Minton E. J., Smillie D., Neal K. R., Irving W. L., Underwood J. C., James V. Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. J Infect Dis. 1998 Jul;178(1):39–44. doi: 10.1086/515599. [DOI] [PubMed] [Google Scholar]
  30. Mosnier J. F., Degott C., Marcellin P., Hénin D., Erlinger S., Benhamou J. P. The intraportal lymphoid nodule and its environment in chronic active hepatitis C: an immunohistochemical study. Hepatology. 1993 Mar;17(3):366–371. [PubMed] [Google Scholar]
  31. Nishioka K., Watanabe J., Furuta S., Tanaka E., Suzuki H., Iino S., Tsuji T., Yano M., Kuo G., Choo Q. L. Antibody to the hepatitis C virus in acute hepatitis and chronic liver diseases in Japan. Liver. 1991 Apr;11(2):65–70. doi: 10.1111/j.1600-0676.1991.tb00494.x. [DOI] [PubMed] [Google Scholar]
  32. Ockenga J., Tillmann H. L., Trautwein C., Stoll M., Manns M. P., Schmidt R. E. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol. 1997 Jul;27(1):18–24. doi: 10.1016/s0168-8278(97)80274-7. [DOI] [PubMed] [Google Scholar]
  33. Okamoto H., Kobata S., Tokita H., Inoue T., Woodfield G. D., Holland P. V., Al-Knawy B. A., Uzunalimoglu O., Miyakawa Y., Mayumi M. A second-generation method of genotyping hepatitis C virus by the polymerase chain reaction with sense and antisense primers deduced from the core gene. J Virol Methods. 1996 Mar;57(1):31–45. doi: 10.1016/0166-0934(95)01960-x. [DOI] [PubMed] [Google Scholar]
  34. Peano G., Menardi G., Ponzetto A., Fenoglio L. M. HLA-DR5 antigen. A genetic factor influencing the outcome of hepatitis C virus infection? Arch Intern Med. 1994 Dec 12;154(23):2733–2736. doi: 10.1001/archinte.1994.00420230126015. [DOI] [PubMed] [Google Scholar]
  35. Rehermann B., Seifert U., Tillmann H. L., Michel G., Böker K. H., Pichlmayr R., Manns M. P. Serological pattern of hepatitis C virus recurrence after liver transplantation. J Hepatol. 1996 Jan;24(1):15–20. doi: 10.1016/s0168-8278(96)80180-2. [DOI] [PubMed] [Google Scholar]
  36. Rigas B. HLA and disease association: the case of gastric cancer. Gastroenterology. 1996 Aug;111(2):523–526. doi: 10.1053/gast.1996.v111.agast961110523. [DOI] [PubMed] [Google Scholar]
  37. Sheehan M. M., Doyle C. T., Whelton M., Kenny-Walsh E. Hepatitis C virus liver disease in women infected with contaminated anti-D immunoglobulin. Histopathology. 1997 Jun;30(6):512–517. doi: 10.1046/j.1365-2559.1997.5530803.x. [DOI] [PubMed] [Google Scholar]
  38. Steel C. M., Ludlam C. A., Beatson D., Peutherer J. F., Cuthbert R. J., Simmonds P., Morrison H., Jones M. HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet. 1988 May 28;1(8596):1185–1188. doi: 10.1016/s0140-6736(88)92009-0. [DOI] [PubMed] [Google Scholar]
  39. Stuyver L., Rossau R., Wyseur A., Duhamel M., Vanderborght B., Van Heuverswyn H., Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol. 1993 Jun;74(Pt 6):1093–1102. doi: 10.1099/0022-1317-74-6-1093. [DOI] [PubMed] [Google Scholar]
  40. Svejgaard A., Ryder L. P. HLA and disease associations: detecting the strongest association. Tissue Antigens. 1994 Jan;43(1):18–27. doi: 10.1111/j.1399-0039.1994.tb02291.x. [DOI] [PubMed] [Google Scholar]
  41. Thursz M. R., Kwiatkowski D., Allsopp C. E., Greenwood B. M., Thomas H. C., Hill A. V. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med. 1995 Apr 20;332(16):1065–1069. doi: 10.1056/NEJM199504203321604. [DOI] [PubMed] [Google Scholar]
  42. Thursz M., Yallop R., Goldin R., Trepo C., Thomas H. C. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet. 1999 Dec 18;354(9196):2119–2124. doi: 10.1016/s0140-6736(99)91443-5. [DOI] [PubMed] [Google Scholar]
  43. Tibbs C., Donaldson P., Underhill J., Thomson L., Manabe K., Williams R. Evidence that the HLA DQA1*03 allele confers protection from chronic HCV-infection in Northern European Caucasoids. Hepatology. 1996 Dec;24(6):1342–1345. doi: 10.1053/jhep.1996.v24.pm0008938158. [DOI] [PubMed] [Google Scholar]
  44. Tillmann H. L., Manns M. P. Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups. Dig Dis Sci. 1996 Dec;41(12 Suppl):27S–40S. doi: 10.1007/BF02087874. [DOI] [PubMed] [Google Scholar]
  45. Tillmann H., Trautwein C., Walker D., Michitaka K., Kubicka S., Böker K., Manns M. Clinical relevance of mutations in the precore genome of the hepatitis B virus. Gut. 1995 Oct;37(4):568–573. doi: 10.1136/gut.37.4.568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Tong M. J., el-Farra N. S., Reikes A. R., Co R. L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995 Jun 1;332(22):1463–1466. doi: 10.1056/NEJM199506013322202. [DOI] [PubMed] [Google Scholar]
  47. Tremolada F., Casarin C., Tagger A., Ribero M. L., Realdi G., Alberti A., Ruol A. Antibody to hepatitis C virus in post-transfusion hepatitis. Ann Intern Med. 1991 Feb 15;114(4):277–281. doi: 10.7326/0003-4819-114-4-277. [DOI] [PubMed] [Google Scholar]
  48. Verdon R., Pol S., Landais P., Mattlinger B., Carnot F., Brechot C., Busson M., Kreis H. Absence of association between HLA antigens and chronicity of viral hepatitis in haemodialyzed patients. J Hepatol. 1994 Sep;21(3):388–393. doi: 10.1016/s0168-8278(05)80318-6. [DOI] [PubMed] [Google Scholar]
  49. Vitte R. L., Fortier C., Richardet J. P., Grimbert S., Trinchet J. C., Beaugrand M., Lepage V., Raffoux C. HLA antigens in patients with chronic hepatitis C. Tissue Antigens. 1995 May;45(5):356–361. doi: 10.1111/j.1399-0039.1995.tb02467.x. [DOI] [PubMed] [Google Scholar]
  50. Wawrzynowicz-Syczewska M., Underhill J. A., Clare M. A., Boron-Kaczmarska A., McFarlane I. G., Donaldson P. T. HLA class II genotypes associated with chronic hepatitis C virus infection and response to alpha-interferon treatment in Poland. Liver. 2000 Jun;20(3):234–239. doi: 10.1034/j.1600-0676.2000.020003234.x. [DOI] [PubMed] [Google Scholar]
  51. Yuki N., Hayashi N., Takehara T., Hagiwara H., Hiramatsu N., Naito M., Kawanishi Y., Katayama K., Kasahara A., Fusamoto H. Serum hepatitis C virus RNA levels and liver injury in volunteer blood donors. Am J Gastroenterol. 1994 Sep;89(9):1462–1466. [PubMed] [Google Scholar]
  52. Zavaglia C., Bortolon C., Ferrioli G., Rho A., Mondazzi L., Bottelli R., Ghessi A., Gelosa F., Iamoni G., Ideo G. HLA typing in chronic type B, D and C hepatitis. J Hepatol. 1996 Jun;24(6):658–665. doi: 10.1016/s0168-8278(96)80260-1. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES